D-Tyr—Ser—Gly—Phe—Leu—Thr, a highly preferential ligand for δ-opiate receptors  by Gacel, Gilles et al.
I)-TYR-SER--GLY-PHE-LEU-THR, A HIGHLY PREFERENTIAL LIGAND FOR 
6-OPIATE RECEPTORS 
Gilles GACEL, Marie-Claude FOURNIE-ZALUSKI and Bernard P. ROQUES 
~~~rteinent de Chimie Urganique, ERA 6 I3 du CNRS, UER des Sciences Pharmaceutiques et Biologiques, 4 avenue de 
~‘~~servatoire~ 75270 Paris Cedex 06, France 
Received 11 July 1980 
1. Introduction 
Binding studies of radiolabeled enkephalins with 
brain homogenates [l-3] suggest hat these peptides 
interact with at least two distinct classes of binding 
sites called p and S receptors. Enkephalins bind to 
6 receptors which constitute almost 20% of the total 
binding with a high affinity (Kd _ 0.5 nM and to 
&f receptors with a lower af~nity (Kd - 5 nM) [ 1,2]. 
Furthermore, displacement experiments with antago- 
nists show that morphine and synthetic opiates inter- 
act strongly with g receptors whereas peptides exhibit 
a high preference for 6 receptors [ 1,2,4]. Such results 
were also found in peripheric organs and attributed 
to the preponderance of g receptors in the guinea pig 
ileum (GPI) and 6 receptors in the mouse vas deferens 
(MVD) [l-4]. Therefore, the difference in the phar- 
macological action of any compound on the two 
organs was used to evaluate its p and 6 specificity [4]. 
The biological significance of the presence of +U 
and 6 receptors in the brain remains still unknown 
although it seems that p receptors could be involved 
in analgesia [4] whereas 6 receptors might be impli- 
cated in behavioral effects [S] . A possible dissocia- 
tion of the pharmacological responses associated to 
multiple opiate receptors have incited a great number 
of studies in vivo [6.173 and in vitro [3,7] for the last 
months. 
However. these studies were perfo~ed with 
D-Ala’-D-LeuS enkephalin (DADL), a compound 
which exhibits only a partial specificity for 6 receptors 
141. Therefore it was of great importance to search 
for a much higher specific ligand, in order to avoid 
multiple biological responses arising from simulta- 
neous binding to the two kinds of states. Starting 
from conformational data and structure activity rela- 
tionships in the enkephalin series, such a compound 
was prepared. This new hexapeptide Tyr-D-Ser- 
Gly-Phe-Leu-Thr exhibits a very high specificity 
for 6 receptor, since its potency is 620-times greater 
in MVD (f& = 0.58 nM) than in GPI (K’,, = 360 nM). 
2. Materials and methods 
2.1. Synthesis 
Protected aminoacids used in this synthesis were 
purchased from Bachem (Switserland). Met-enkephalin 
and Leu-enkephalin were prepared as in [8,9]. 
Tyr-D-Ser-Gly-Phe-Leu-Thr has been pre- 
pared by liquid phase method using terbutyloxycar- 
bony1 (Boc) and methylesters as protecting groups 
and dicyclohexylcarbodiimide (DCC) with hydroxy- 
benzotriazole as coupling reagents [8,10]. The depro- 
tection steps were done using trifluoroacetic acid 
(TFA) for Boc group and saponification by NaOH 
for methyl esters. During the synthesis the structure 
of the different compounds was confirmed by NMR 
spectroscopy (Briiker WH 270 MHz) in DMSOd6 and 
their purity was checked by thin-layer chromatog- 
raphy on silica-gel glass plate using: (A) n-BuOH/ 
AcOH(H20, 4/1/l ; (B) CHCla/MeOH, 9/l ; or (C) 
CHClS/MeOH, 9/l, as solvents. 
The different steps of the synthesis of Tyr-D- 
Ser-Gly-Phe-Leu-Thr are summarized in scheme 1. 
The protection of D-Ser and Thr hydroxyl groups 
allowed us to obtain high yields in every step. 
The final compound was obtained by deprotection 
of both N-terminal group and lateral chains, by stir- 
ring with HCl 1 N in TFA during 30 min. The solution 
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Phe Thr ~1 incubates were collected at intervals of 10 min and 
injected in the same conditions as in section 2.2. The 
detection was performed at 210 nm. No significant 
degradation seems to occur after 1 h as shown by the 
absence of change in the hexapeptide signal. 
3. Results and discussion 
We have shown that the phenylalanine moiety 
plays a crucial role in the differential recognition of 
enkephalins to p and 6 receptors [ 1 I]. Therefore the 
design of a specific ligand for S receptors was based 
on the following considerations: 
Scheme 1 (i) 
was concentrated in vacua and a white powder pre- 
cipitated by addition of Et,O. The crude product was 
purified by gel filtration on LH 20 (Pharmacia) using 
MeOH as solvent. 
(ii) 
The hexapeptide is characterized by a single peak 
(retention times = 6 12 s) in high performance liquid 
chromatography (HPLC) on a reverse phase micro- 
bondapak C 18; solvent CH,CN/lO mM, NH4Ac 
buffer (pH 4.2) 20/80, flowrate 1.2 ml/min. The ‘H 
NMR chemical shifts (10m2 M in DMSOd6 with 
HMDS as internal reference) for Tyr-D-Ser-Gly- 
Gly-Leu-Thr are: Tyr, OH = 9.17, H, = 6.97, 
Ho = 6.61, H, = 3.62; D-Ser, NH = 8.37, H, = 4.14, 
0H=5.33;Gly,NH=8.20.CH2=3.65;Phe, 
NH = 8.02, H, = 4.41; Leu, NH = 8.32, H, = 4.10. 
CHJ = 0.78; Thr, NH = 7.33, H, = 3.81, CH3 = 0.86, 
OH = 4.96. 
(iii) 
As reported [ 121 the lengthening of Met-enke- 
phalin by addition of a Thr residue on the C-ter- 
minal methionine enhances the potency on MVD 
and decreases the activity on GPI. 
Leu-enkephalin shows a significant increased 
potency on MVD as compared to Met-enkephalin 
[II; 
The replacement of Gly2 by a D-amino acid 
inhibits the degradation of the peptide by amino- 
peptidases [ 131 and reinforces preferentially the 
binding to the /J receptor when the side chain of 
this D-amino acid is of hydrophobic nature [ 141. 
2.2. Pharmacological assays 
Opioid activity was evaluated on GPI and on MVD 
as in [lo]. Six different concentrations of each com- 
pound (6-8 assays for each) were tested for the inhi- 
bition of electrically induced contractions. ZCsO were 
determined by regression analysis. According to [4]. 
methionine-enkephalin was used in each assay as 
internal standard to avoid differences of sensitivity 
of each preparation. 
These features lead to the synthesis of the hexapep. 
tide Tyr-D-Ser-Gly-Phe-Leu-Thr. As shown in 
table 1, this compound exhibits a considerable 
increased potency on MVD as compared to Met- 
enkephalin which has been taken as a reference [4]. 
Moreover, at variance with Tyr-D-Ala-Gly-Phe- 
D-Leu, the introduction of D-Ser in the hexapeptide 
leads to a large decrease in activity on the GPI. Con- 
sequently the ratio of inhibitory potency on GPI 
(/J receptors) to MVD (6 receptors) is much higher 
for the hexapeptide (GPI/MVD = 620 than for the 
pentapeptide, GPI/MVD = 88. 
From this large variation in activity on the two 
isolated organs. Tyr-D-Ser-Gly-Phe-Leu-Thr can 
be considered as a highly specific ligand for 6 recep- 
tors and should allow a complete dissociation of the 
pharmacological responses according to its binding 
with a single class of receptors. 
2.3. Degradation study 
The enzymatic stability of Tyr-D-Ser-Gly-Phe- 
Leu-Thr was checked by incubation with membranes 
from mouse striatum as in [lo]. The peptide was dis- 
solved in 1 ml P2 fraction (1 mg protein/ml corre- 
sponding to 10 mg tissue) at 10” M. AIiquots of 10 
Furthermore, Tyr-D-Ser-Gly-Phe-Leu-Thr is 
not significantly degraded after 1 h incubation with 
mouse striatal membranes. This property results both 
from the replacement sf Gly’ by D-Ser’ inhibiting 
the action of aminopeptidases [131 and from the 
addition of a threonine residue at the C-terminal part 
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Table 1 
Comparison of the inhibitory effects on guinea pig ileum and mouse vas deferens between 
enkephalins, Tyr-D-Ala-Gly-Phe-D-Leu and Tyr-D-Ser-Gly-Phe-Leu-Thr 
Peptide Inhibition of contractions (IC,,, nM) IC,,GPl/ 
IC,,MVD 
Guinea pig ileum Mouse vas deferens 
- __~ 
Tyr-Gly-Gly--Phe-Met (Met-E) 200.0 f 19 (6) 13.00 + 1.50 (6) 15.4 
Tyr-Gly-Gly-Phe-Leu (Leu-E) 455.0 f 53 (6) 8.82 f 1.20 (6) 51.6 
Tyr-D-Ala-Gly-Phe-D-Leua 47.8 + 4.4 (4) 0.54 + 0.09 (5) 88.5 
Tyr--D-Ser-Gly-Phe-Leu-Thr 360.0 f 28 (8) 0.58 f 0.20 (8) 620.7 
a From [4] 
The values are the means t SEM: the no. obs. is given in parentheses 
of the peptide preventing its degradation by enke- 
phalinase [15,16]. 
Therefore, this compound could be of great inter- 
est to confirm the very promising results on the lack 
of cross-tolerance between 6 receptor agonists and 
p receptor agonists [6], as well as to investigate the 
chemical differences between the two receptors at 
the molecular level of highly selective protection 
experiments [7]. 
Finally, despite the smaller concentration of 
6 receptors in the brain, Tyr-D-Ser-Gly-Phe-Leu- 
Thr could be used to evaluate the regional distribu- 
tion of this kind of sites. For such purposes radio- 
labeling of this peptide is now in progress. 
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